


A COMPREHENSIVE INTELLIGENCE REPORT ON

# ONCOLOGY DRUG FUNDING 2013



A Comprehensive Intelligence Report on

---

# **ONCOLOGY DRUG FUNDING 2013**

---

Sample Pages

Table A.1: Investment Summary of 321 Investor Firms.

Funds Name	Investment Focus				Fund under Management in Mn USD	Investment Preference	Investment Range in Mn USD	Fund Focused	Active Portfolio	
	Angel	Early	Mid	Late					Total Comp	Oncology Comp
3i Group plc				✓	5000+	Worldwide	-	Diversified	101	1
5AM Ventures		✓	✓		101 - 500	USA, Europe	-	Life Science	31	4
Aberdare Ventures		✓	✓		101 - 500	USA	1 - 15	Healthcare	29	1
Abingworth LLP		✓	✓	✓	1001 - 5000	Worldwide	20 - 80	Health Care	100+	1
ABS Ventures		✓	✓		1 - 100	USA	5 - 15	Diversified	60+	1
Adams Street Partners, LLC				✓	5000+	USA	5 - 20	Diversified	157	3
Advanced Technology Ventures		✓	✓		1001 - 5000	USA	-	Diversified	75	4
Advantage Capital Partners			✓	✓	1001 - 5000	USA	0.5 - 10	Diversified	146	2
Advent Venture Partners			✓	✓	201 - 1000	USA, Europe	8 - 25	Diversified	51	7*
Aescap Venture			✓		101 - 500	Europe	0.5 - 7	Biomedical	12	4
Aglaia Biomedical Ventures B.V		✓	✓		1 - 100	Europe	-	Life Science	6	5
Aisling Capital				✓	1000 - 5000	USA	20 - 50	Healthcare	62	3
Alafi Capital Company LLC			✓	✓	1 - 100	USA, Europe	-	Healthcare	11	1
Alliance Technology Ventures		✓	✓		101 - 500	USA	0.5 - 5	Diversified	30	1
Alloy Ventures		✓			501 - 1000	USA	1 - 5	Diversified	31	1
Alta Partners		✓	✓	✓	1001 - 5000	USA, Europe	-	Diversified	65	8
Amgen Ventures		✓			1 - 100	USA, Europe	1 - 10	Biotechnology	12	4
Anthem Capital Management		✓	✓		1 - 100	USA	1 - 5	Diversified	7	1
Aperture Venture Partners, LLC		✓	✓		501 - 1000	USA, Europe	1 - 4	Healthcare	6	1
Apjohn Ventures Fund		✓			1 - 100	USA	0.5 - 2	Life Science	9	2
Apple Tree Partners		✓	✓		101 - 500	USA	-	Life Science	4	2
Apposite Capital LLP		✓	✓	✓	101 - 500	USA, Europe	5 - 15	Healthcare	9	4
Aravis SA		✓	✓		101 - 500	Worldwide	1 - 10	Diversified	15	3
Arboretum Ventures		✓	✓		101 - 500	USA	3 - 7	Healthcare	20	1
ARCH Venture Partners		✓	✓		1001 - 5000	USA	-	Diversified	30	11
Arcus Ventures		✓	✓		101 - 500	USA	-	Life Science	8	3
Ascension Health Ventures		✓	✓		501 - 1000	USA	10 - 15	Healthcare	21	1
Astellas Venture Management			✓		1 - 100	Worldwide	-	Biotechnology	16	5
Athenian Venture Partners		✓			1 - 100	USA	1 - 5	Diversified	23	1
Atlas Venture		✓	✓		1001 - 5000	USA, Europe	0.5 - 5	Diversified	66	2
Auriga Partners		✓	✓		101 - 500	Worldwide	1 - 5	Diversified	37	2
Aurora Funds		✓	✓		101 - 500	USA	0.05 - 2.5	Diversified	23	2
Aurum Ventures MKI		✓	✓		1 - 100	Asia	Up to 10	Diversified	11	1
Avalon Ventures		✓	✓		101 - 500	USA	-	Diversified	55	5
Avlar BioVentures Ltd		✓			101 - 500	Europe	-	Life Science	10	2
AXA Private Equity		✓	✓	✓	5000+	Worldwide	-	Diversified	85	3
Bain Capital Ventures		✓	✓	✓	1001 - 5000	USA	0.1 - 50	Diversified	65	1
Baird Capital		✓	✓	✓	1001 - 5000	Worldwide	1 - 10	Diversified	55	3
Ballast Point Ventures			✓		101 - 500	USA	2 - 5	Diversified	12	1
Bay City Capital LLC		✓	✓		1001 - 5000	Worldwide	-	Life Science	25	4
Bayern Kapital GmbH		✓	✓		101 - 500	Europe	-	Diversified	20+	3

\* Oncology Exit Company

# ONCOLOGY PORTFOLIO COMPANIES INFOGRAPHICS – EUROPE & ASIA

**Figure B.5: Country wise Distribution of Investors and their 152 Portfolio Companies in Europe and Asia.**

In many European countries including Germany and France the ratio between active companies and total number of Investors present in the region is going down, which may signifies that oncology funding was once very active in the region, but at present loosing its charm among investors. Also our previous studies shows that the European region does not see any dampening effect in the number of oncology based start-ups, which implies that now innovators are relying more on other sources of money esp. from Government Funding etc.



**Figure B.6: Total Investor Firms Vs. their Active Portfolio Companies & Exit Companies in Europe.**

Out of 32 Portfolio Companies Exit; 18 are through IPO and 12 are through M&A activities.



**Figure B.7: Total Investor Firms Vs. their Active Portfolio Companies & Exit Companies in Asia.**

In Asia maximum Exits are through Initial Public Offerings (IPO). Israel is the major number contributing country and is also credited to have largest number of technology based oncology start-ups in Asia, much ahead of Japan and China.

# ONCOLOGY PORTFOLIO COMPANIES INFOGRAPHICS – USA

**Figure B.8: State wise Distribution of Investors and their 282 Portfolio Companies in USA.**

Many of the USA states like Massachusetts, Washington, Indiana, Maryland etc. have fairly high ratio of Investors to active portfolio cancer companies in the regions, thus are showing positive funding environment towards oncology funding, and is showing no dampening effect in any of the state; also with healthy Exit portfolio investors are betting more on good ideas.



**UNITED STATES AMERICA**



**CALIFORNIA**

**Figure B.9: Total Investor Firms Vs. their Active Portfolio Companies & Exit Companies in USA.**

**Figure B.10: Total Investor Firms Vs. their Active Portfolio Companies & Exit Companies in California.**

Table B.1: Funding Series Details and Co-Investors Summary of Active Portfolio Oncology Companies.

COMPANY	THERAPEUTIC AREA	FOCUS AREA	ONCOLOGY PIPELINE	KEY TECHNOLOGY PLATFORM	COLLABORATION	SERIES A	SERIES B	SERIES C	SERIES D	SERIES E	SERIES F	NA
4-Antibody AG	Oncology, Infectious, Autoimmune, Inflammatory Diseases	Treatment	Undisclosed (discovery)	Retrocyte Display®	Boehringer Ingelheim Evotec AG Human Genome Sciences Recepta Biopharma	Advent Venture, BioMed Partners, Grazia Equity, Life Sciences Partners [18.5 Mn USD/2007]						
Aarden Pharmaceuticals	Oncology, Infectious, Autoimmune, Metabolic Diseases	Treatment										Elevate Ventures [0.5 Mn/2009]
Acacia Pharma	Oncology	Supportive Care	APD421 (clinical) APD403 (clinical) APD515 (clinical) APD209 (clinical)			Gilde Healthcare, Lundbeckfond Ventures [10 Mn USD/2011]						
Acceleron Pharma	Oncology, Hematologic, Musculoskeletal Disorders	Treatment	Dalantercept/ACE-041 (clinical)		Celgene Corp, Shire plc, Alkermes	Advanced Technology, Avalon Ventures, Flagship Ventures, Polaris Venture, Sutter Hill Ventures Venrock [25 Mn USD/2004]	Advanced Technology, Avalon Ventures, Flagship Ventures, Polaris Venture, Sutter Hill Ventures, Venrock, OrbiMed Advisors [30 Mn USD/2006]	Advanced Technology, Avalon Ventures, Flagship Ventures, Polaris Venture, Sutter Hill Ventures, Venrock, OrbiMed Advisors, Bessemer Venture [31 Mn USD/2007]	Advanced Technology, Avalon Ventures, Flagship Ventures, Polaris Venture, Sutter Hill Ventures, Venrock, OrbiMed, Bessemer Venture [30 Mn USD/2011]			
Acerta Pharma	Oncology, Autoimmune Diseases	Treatment	Undisclosed (discovery)			BioGeneration Ventures, Life Sciences & Health Fund [Undisclosed/2013]						
ACT Biotech	Oncology	Treatment	Telatinib/BAY 57-9352 (clinical) ACTB1003 (clinical) ACTB1010 (IND) ACTB1011 (preclinical)			NGN Capital [24 Mn USD/2008]						
Actinobac Biomed	Oncology, Autoimmune Diseases	Treatment	Leukothera™									Foundation Venture Capital [0.6 Mn/2012]
Acylin Therapeutics	Oncology, Metabolic, Neurodegeneration Disorders	Treatment		Lysine protein acetylation		ARCH Venture Partners, OVP Venture Partners, WRF Capital [4.4 Mn USD/2011]						
Aduro Biotech	Cancer, Infectious Diseases	Treatment	CRS-207 (clinical) ADU-623 (Preclinical) Lm Prostate (Preclinical) Lm Melanoma (Preclinical) STINGVAX (Discovery)	Listeria monocytogenes			Morningside Group [19.2 Mn USD/2011]					
Advanced Cell Diagnostics	Oncology	Diagnostics	RNAScope HPV HNC (clinical) RNAScope HPV CC (clinical) RNAScope MELA (clinical) RNAScope LCR (discovery) RNAScope HER2 (discovery) CTCscope (discovery)	RNAScope®		Morningside Group [5.4 Mn USD/2009]	Morningside Group [12 Mn USD/2012]					
Aerpio Therapeutics	Oncology, Retinopathy, Inflammatory Diseases	Treatment	AKB-9089 (discovery)			AgeChem Ventures, Athenian Venture Partners, Kearny Venture Partners, Novartis Venture Funds, Triathlon Medical Ventures, [27 Mn USD/2012]						
Affimed Therapeutics	Oncology, Inflammatory Diseases	Treatment	AFM-13 (clinical) AFM-11 (preclinical) AFM-12 (preclinical) AFM-20 (discovery)	TandAb®			BioMedPartners, Life Sciences Partners, Novo Nordisk Biotech [45 Mn USD/2008]	BioMedPartners, Life Sciences Partners, Novo Nordisk Biotech, OrbiMed Advisors [26.3 Mn USD/2010]	BioMedPartners Life Sciences Partners, Novo Nordisk Biotech, OrbiMed Advisors [20.4 Mn USD/2012]			
Agendia BV	Oncology	Diagnostics	Symphony™ Breast Cancer Suite (MammaPrint®, Blueprint™, TargetPrint® and TheraPrint®) (approved) ColoPrint® (clinical)		AstraZeneca, Agilent Technologies,	AXA Private Equity, Gilde Healthcare, Global Life Science [Undisclosed/2004]	AXA Private Equity, Gilde Healthcare, Global Life Science [Undisclosed/2005]	AXA Private Equity, Gilde Healthcare Partners, Global Life Science [Undisclosed/2006]	AXA Private Equity, Gilde Healthcare, Global Life Science [35 Mn USD/2007]	AXA Private Equity, Gilde Healthcare, Global Life Science [23 Mn USD/2009]	AXA Private, Gilde Healthcare, Global Life Science [65 Mn/2012]	
Agios Pharmaceuticals	Oncology, Genetic Diseases	Treatment	Undisclosed (discovery)		Celgene Corporation	ARCH Venture Partners, Flagship Ventures, Third Rock Ventures [33 Mn USD/2008]	ARCH Venture Partners, Flagship Ventures, Third Rock Ventures [8.8 Mn USD/2010]	ARCH Venture Partners, Flagship Ventures, Third Rock Ventures [78 Mn USD/2011]				

Table B.2: Funding Series Details and Co-Investors Summary of Exit Portfolio Oncology Companies.

COMPANY	THERAPEUTIC AREA	FOCUS AREA	EXIT YEAR	EXIT STRATEGY	VALUE (MN USD)	SERIES A	SERIES B	SERIES C	SERIES D	SERIES E	SERIES F	NA*
3-Dimensional Pharmaceuticals	Oncology, Inflammation, Metabolic and Cardiovascular Diseases	Treatment	2003	Acquired by J&J	\$88							Rho Ventures
Ablynx	Oncology, Inflammation, Hematology, and Pulmonary Diseases	Treatment	2007	IPO		GIMV	GIMV	GIMV				
AcelRx	Pain	Treatment	2011	IPO		Pinnacle Ventures, Skyline Ventures, Three Arch Partners	Pinnacle Ventures, Skyline Ventures, Three Arch Partners					
Adherex Technologies	Oncology	Treatment	2007	IPO								VIMAC Ventures
Adnexus Therapeutics	Oncology, and Immunology	Treatment	2007	Acquired by BMS	\$505	Atlas Venture, Flagship Ventures, HBM Healthcare, Polaris Venture	Atlas Venture, Flagship Ventures, HBM Healthcare, Polaris Venture, Venrock	Atlas Venture, Flagship Ventures, HBM Healthcare, Polaris Venture, Venrock				
ADVENTRX Pharmaceuticals	Oncology, and Hematology	Treatment	2000	IPO								Tech Coast Angels
Affitech	Oncology, and Inflammatory Diseases	Treatment	2010	IPO								Teknoinvest
Agennix	Oncology, and Diabetes complications	Treatment	2009	IPO								Dievini Hopp
Agensys	Oncology	Treatment	2007	Acquired by Astellas	\$537				Alta Partners, HBM Healthcare, Nextech Invest			
Agenus	Oncology, and Infectious Diseases	Treatment	2000	IPO								Flagship Ventures
Alchemia Limited	Oncology	Treatment	2003	IPO								CM Capital Investments
Aldagen	Oncology, and Cardiovascular Disorders	Treatment	2012	Acquired by Cytomedix	\$40			Harbert Venture Partners, Intersouth Partners, Piedmont Angel Network, Tall Oaks Capital Partners	Aurora Funds, Intersouth Partners			
Alerion Biomedical	Oncology, Cardiovascular, and CNS Disorders	Imaging	2006	Acquired by ART Advanced Research Technologies	Undisclosed							Research Corporation Technologies
Algeta	Oncology	Treatment	2007	IPO		Advent Venture Partners, Birk Venture, HealthCap						
Allos Therapeutics	Oncology	Treatment	2000	IPO		Abingworth, Aisling Capital, New Leaf Venture, Sequel Venture Partners, SV Life Sciences	Abingworth, Aisling Capital, New Leaf Venture, Sequel Venture Partners, SV Life Sciences					
Alnylam Pharmaceuticals	Oncology, Bleeding Disorders, Cardiovascular Disorder, and others	Treatment	2004	IPO		Abingworth, Atlas Venture, Cardinal Partners, Polaris Venture, Roche Venture	Abingworth, ARCH Venture Partners, Atlas Venture, Cardinal Partners, Polaris Venture, Roche Venture					
Altiris Therapeutics	Oncology	Treatment	2005	Acquired by Celldex Research	Undisclosed							BioAdvance
Anesta Corporation	Cancer Pain	Treatment	2000	Acquired by Cephalon	\$444							Flagship Ventures
AnGes MG	Oncology, CNS, Cardiovascular Disorders, and others	Treatment	2002	IPO								Mitsubishi UFJ Capital Co
Antsoma	Oncology	Treatment	2005	IPO								CDIB BioScience, HealthCare Ventures, Roche Venture
Aposense	Oncology	Molecular Imaging & Treatment	2010	IPO		Clal Biotechnology, MediTech Partners						

\* Key Investors



**GENERAL INFORMATION**

**Investor Name:** Adams Street Partners, LLC  
**Managed By:** NA  
**Founded in:** 1972  
**Focus:** Diversified  
**Fund Type:** Private Equity  
**Total Portfolio Companies:** 157  
**Active Cancer Focused Companies in Portfolio:** 3  
**Fund under Management:** \$22,000 Mn USD  
**Address:** One North Wacker Drive, Suite 2200 Chicago, Illinois 60606-2823 U.S.A  
**URL:** www.adamsstreetpartners.com  
**Email:** mokincicas@adamsstreetpartners.com  
**Ownership:** Private  
**Exchange:** NA    **Ticker:** NA    **Market Capitalization:** NA

**ABOUT FUND**

- » Adams Street Partner is a private equity investment, employee-owned private equity firm and is one of the largest managers of private equity for institutional investors.
- » Adams Street Partners’ Direct Team invests \$5-20 million in companies seeking venture capital or growth equity to accelerate their businesses or to provide partial liquidity for existing shareholders. Each year roughly 10 new companies are provided funds through this channel.
- » Firm invest into fast-growing and late stage companies in the Technology and Life Sciences (Biopharmaceuticals/ Medical devices) sectors.
- » The firm seeks to invest in companies predominantly that are based in the United States.
- » It invests in companies that have received prior financing from early-stage venture firms and are seeking additional capital to fund product development & commercialization.


**MANAGEMENT PROFILES**



**Terry Gould**  
*Head of Direct Investments*  
 tgould@adamsstreetpartners.com

*Terry Gould* joined in 1994 and is the Head of Direct Investments for medical device and biopharma sectors. He sits on the Boards of Directors of Incline Therapeutics, Neuraltus, Proteus Digital and OncoMed. He is responsible for several other successful investments: CombiChem, Heartport, INC Research, Jazz Pharma, NxStage, Revivant, Spinal Dynamics and Vivant Medical. He did BA from Dartmouth College & MBA from Stanford University.

**Assistant:** Victoria Long    **e-mail:** vlong@adamsstreetpartners.com    [Linked in profile](#)



**Michael Lynn**  
*Partner*  
 mlynn@adamsstreetpartners.com

*Michael Lynn* joined in 2007 and is responsible for sourcing and screening private equity investments in the medical device and biopharmaceutical sectors. Mike serves on the Boards of Directors of Luminous Medical, MyHealthTeams, Pivot Medical, PneumRx, Revascular, TriReme and USGI Medical and is a Board Observer at GlobelImmune. He did BA from Carleton College and MD from UCLA School of Medicine.

**Assistant:** Nancy Thomsen    **e-mail:** nthomsen@adamsstreetpartners.com    [Linked in profile](#)



**Thomas Bremner**  
*Principal*  
 tbremner@adamsstreetpartners.com

*Thomas Bremner* joined Adams Street Partners in 2013 and is responsible for sourcing and leading late stage venture and growth equity investments in the technology and health care sectors. He did BS from University of Dayton and MBA from University of Chicago Booth School of Business.

**Assistant:** Kirsten Cimmarusti    **e-mail:** kcimmarusti@adamsstreetpartners.com    [Linked in profile](#)

[Linked in profile](#)

**CURRENT PORTFOLIO COMPANIES**

COMPANY	COUNTRY	KEY AREA	FUNDING (IN USD)	YEAR	DESCRIPTION	CO-INVESTOR
GlobelImmune	USA	Drug discovery & development	\$38.4 Mn (Series B) \$41.2 Mn (Series C) \$10 Mn (Series D) \$17.5 Mn (Series E)	Jan 2006 Sep 2007 May 2009 Jan 2010	Biopharma company developing therapeutic vaccines for the treatment of cancer and infectious diseases.	HealthCare Ventures, Biogen Idec, Lilly Ventures, Celgene, Morgenthaler Ventures, Sequel Venture, Genentech, Medica Venture, Partners Healthcare, GC&H Investments, CIDC, PAC-LINK Bio Venture, Yasuda Enterprise Development, Wexford Capital, BSI SA, Mellon Family Investment Company, Richard King Mellon Foundation, Eminent Venture Capital, Boston Life Science Venture, WRF Capital, Generali Financial Holding



COMPANY	COUNTRY	KEY AREA	FUNDING (IN USD)	YEAR	DESCRIPTION	CO-INVESTOR
Light Sciences Oncology	USA	Drug discovery & development	\$67 Mn (Series A) \$30 Mn (Series B) \$40.1 Mn (Series C)	Dec 2005 Jul 2007 Jul 2008	Engaged in developing light-activated drug products for the treatment of cancer.	Essex Woodlands Health Ventures, Johnson and Johnson, Novo A/S, China Development Industrial Bank, Larkspur Capital Corporation, Scandinavian Life Science Venture, New Science Ventures, Lehman Brothers, Burrill & Co., Deephaven Capital Management, The Malaysian Life Sciences Capital Fund
OncoMed Pharmaceuticals	USA	Drug discovery & development	\$169 Mn (Series B)	Dec 2008	Clinical stage company developing monoclonal antibodies targeting cancer stem cells for the treatment of cancer.	US Venture Partners, Latterell Venture Partners, Vertical Group, Delphi Ventures, Morgenthaler Ventures, DeNovo Ventures, Bay Partners

## EXIT COMPANIES

COMPANY	COUNTRY	KEY AREA	FUNDING (IN USD)	YEAR	DESCRIPTION	CO-INVESTOR
Zalicus (formerly CombinatoRx)	USA	Drug discovery & development	\$40 Mn (Series B) \$30 Mn (Series C)	2006 (IPO)	A biopharma company developing therapies for the treatment of pain and immuno-inflammatory diseases	Boston Millennia Partners, Easton Capital, Yasuda Enterprise Development, Global Life Science Ventures, Canaan Partners, Flagship Ventures, TL Ventures, Novartis BioVentures, Global Life Science Ventures, POSCO BioVentures, CDIB BioScience Ventures, BioVentures Investor
Vivant Medical	USA	Medical device	\$19 Mn (total funding)	2005 (acquired by Valley-lab)	Develops microwave ablation technology for the minimally invasive treatment of benign and cancerous soft tissue tumors	California Technology Ventures, Johnson & Johnson, Pacific Venture Group, Three Arch Partners

## LUNDBECKFOND VENTURES

### GENERAL INFORMATION

**Investor Name:** Lundbeckfond Ventures  
**Managed By:** Lundbeckfond Ventures  
**Founded in:** 2009  
**Focus:** Life Sciences  
**Fund Type:** Venture Capital  
**Current Total Portfolio Companies:** 12  
**Active Cancer Focused Companies in Portfolio:** 4  
**Fund under Management:** \$1 - \$100 Mn USD  
**Address:** Vestagervej 17  
 DK-2900 Hellerup, Denmark  
**URL:** www.lundbeckfondventures.com  
**Email:** mail@lundbeckfondventures.com  
**Ownership:** Private  
**Exchange:** NA **Ticker:** NA **Market Capitalization:** NA

### ABOUT FUND

- » Lundbeckfond Ventures, wholly owned by the Lundbeck Foundation, is a venture capital firm specializing in early stage investments in life science companies.
- » It make investments within life science sector, focusing on pharmaceuticals, biopharmaceuticals, medtech and diagnostics companies.
- » Lundbeckfond Ventures invests up to € 50 Mn in companies primarily located in the Northern Europe.
- » Its present portfolio consists of 12 companies in the active mode of investment from various therapeutic areas.

### MANAGEMENT PROFILES



**Mette Kirstine Agger**  
 Managing Partner  
 mka@lundbeckfonden.dk  
[Linked In profile](#)

*Mette Kirstine Agger* is Managing Partner of Lundbeckfond Ventures. She was previously Co-Founder and CEO of 7TM Pharma and has a broad international experience within biotech/life science covering business development and licensing, management and financing. Prior, Mette was part of the management team of NeuroSearch responsible for business development and licensing. She started her career as Patent Agent. Mette has been appointed to numerous board positions both in private and public companies including Allocure, Psioxus and Veloxis. She is an M.B.A and is graduated as Biologist from the University of Copenhagen.



**Johan Kördel**  
 Senior Partner  
 cjk@lundbeckfonden.dk  
[Linked In profile](#)

*Johan Kördel* is Senior Partner of Lundbeckfond Ventures. He was previously Co-Founder and CEO of Sound Biotech and Co-Founder and Senior VP of Research and Business Development of Biovitrum. Prior to these positions he worked almost a decade in Pharmacia. Johan has co-founded other biotech companies and been appointed to numerous board positions both in private and public companies. Presently, he is a board member of Acacia Pharma, Celladon, Enterome, River Vision and Syntaxin. He is an associate professor in Physical Chemistry at the University of Lund, Sweden.

### CURRENT PORTFOLIO COMPANIES

COMPANY	COUNTRY	KEY AREA	FUNDING (IN USD)	YEAR	DESCRIPTION	CO-INVESTOR
Acacia Pharma	U.K	Cancer management	\$10 Mn (Series A)	Mar 2011	Pharmaceutical company specialising in the development of drugs for cancer supportive care.	Glide Healthcare
PsiOxus Therapeutics	U.K	Drug discovery & development	\$34 Mn (Series B)	Jul 2012	Development-stage biotech company, developing therapeutic vaccines for the treatment of cancer and its related conditions.	Imperial Innovations Group, Invesco Perpetual, SR One
DySIS Medical	UK	Diagnostics	\$11.6 Mn (Undisclosed)	Apr 2013	Medical device company that develops and manufactures imaging systems focusing on the detection of cancerous and pre-cancerous lesions.	Albion Ventures, NBGI, the Scottish Investment Bank
Syntaxin	UK	Drug discovery & development	\$27 Mn (Series C)	Nov 2010	Biopharma company developing biologic drugs (Targeted Secretion Inhibitors) for the treatment of various disorders, including cancer.	Seventure Partners, Ipsen, Abingworth, SR One, Life Science Partners, Johnson & Johnson Development Corporation, Quest for Growth,